Literature DB >> 12746948

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

Curt Parnes, Judith Guillermin, Rolf Habersang, Peggy Nicholes, Vijay Chawla, Tammy Kelly, Judith Fishbein, Patty McRae, Mary Goessler, Antoinette Gatti, John A Calcagno, Cheryl Eki, Kristen A Harris, Joseph Joyave, Kathy McFarland, Paul Protter, Mary Sullivan, Allan Stanford, Nancy Lovett, Marisol Ortiz, Sharon Rojas, Scott Cyrus, Janell Cyrus, Stuart Cohen, Debbie Buchin, Linda Riordan, Monica Zuniga, Rupa Shah, Carmen Minard, Arden Quintin, Glenda Douglas, John van Houten, Sharyn Freutner, Stephen Chartrand, Patsy Nowatzke, Jose Romero, Torunn Rhodes, Michelle Benoit, Emmanuel Walter, Leslie Walker, Laurie DeBonnett, Mia Cross, Teresa Free, Sharman Martin, Karen Shank, Ben Guedes, Lee Ann Atkinson, George J Halpin, Kathy Rouse, Ivan Hand, Donna Geiss, James R Marshall, Lois Burleson, Jim Boland, Kelsey Seybold, Vicki Hunter, Susan Unfer, Jackie Schmucker, Margaret Gley, Michael Marcus, Patricia Thompson, Paulino Milla, Connie Young, Robert Zanni, Virginia Zinno, Alexandra Fetter-Zarzeka, Amanda Busey, Modupe A Sokunbi, Sherrie Airington, Nancy Richard, Vellore Muraligopal, Stephanie Lewis, F Thomas Weber, Beverly P Giordano, Denise Linehan, Jane Roach, Randle Davis, Andrew A Rzepka, Teri Booth, David Smeltzer, Jeanne Walsh, Emilio Arispe, Rhonda Rowley, Christopher Bolling, Tanya Botts, Kateri Haskett, Deana Raby, Evelyn Batiz, Andrew Gelfand, Lynn Farrell, Stephen Butler, Linda Colby, Peter Schochet, Julie Bentler, David Hirsch, Lisa Wilkinson, Allen Aaronson, Eleanora Bennett, Julie Wingate, Dawn Quinn, Katherine Komendowski, Marcia Deckard, Michael Frogel, Cliff Nerwen, Steven Copenhaver, Michele Prater, Jacob Wolsztein, Kristine Mackey, Marshall Benbow, Marisela Naranjo, Sandra Hensley, Cindy Hayes, Hossein Sadeghi, Sally May Lawson, Mark McCall, Karla Combs, Joel Ledbetter, Karen Sarnosky, Cathy Swafford, Michael Speer, Wendy J Barton, J W Mink, Dianne Lemm, Mark Hudak, Elizabeth Case, Judith Rowen, Sandra Fuentes, Carly Pane, Leslie Richardson, Cesar Chavarria, Deanne Cassino, Kourosh Ghaffari, Carol Carroll, Haesoon Lee, Lydia Guclu, Christopher Johnson, Valerie Blum, Marnie L Boron, Mark Sorrentino, Robert L Hirsch, Paul C Van Veldhuisen, Carol Smith.   

Abstract

The objective of the Registry was to characterize the population of infants receiving prophylaxis for respiratory syncytial virus (RSV) disease by describing the patterns and scope of usage of palivizumab in a cross section of US infants. RSV hospitalization outcomes were also described. The Palivizumab (Synagis, MedImmune, Inc., 25 West Watkins Mill Road, Gaithersburg, MD 20878) Outcomes Registry was a prospective multicenter survey conducted at 63 sites. Demographics, injection history, and RSV hospitalization outcomes were collected on 2,116 infants receiving palivizumab. Infants were enrolled in the Registry between September 1, 2000-March 1, 2001, at the time of their first injection. Infants born at less than 32 weeks of gestation accounted for 47% of infants enrolled, and those between 32-35 weeks accounted for 45%; approximately 8% were greater than 35 weeks of gestation. Lower RSV hospitalization rates were observed in infants who had greater adherence to regularly scheduled injections. Nearly one-half of all hospitalizations occurred within the first and second injection intervals, suggesting the importance of early RSV protection. The confirmed RSV hospitalization rate of all infants in the Registry was 2.9%; the rate was 5.8% in infants with chronic lung disease of infancy, and 2.1% in premature infants without chronic lung disease. In conclusion, these data support the continued effectiveness of palivizumab prophylaxis for severe RSV lower respiratory tract disease in a large cohort of high-risk infants from geographically diverse pediatric offices and clinics. The Palivizumab Outcomes Registry provides an opportunity to assess palivizumab utilization and clinical effectiveness in the US. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746948     DOI: 10.1002/ppul.10288

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  39 in total

1.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

2.  Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.

Authors:  B Resch; W Gusenleitner; W D Müller; J Haas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

3.  Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study.

Authors:  Giacomo Pongiglione; Alessandro Possidoni; Umberto di Luzio Paparatti; Anna Maria Costanzo; Giuliana Gualberti; Marco Bonvicini; Alessandro Rimini; Gabriella Agnoletti; Maria Pia Calabrò; Marco Pozzi; Roberto Tumbarello; Patrizia Salice; Patrizio Fiorini; Maria Giovanna Russo; Ornella Milanesi
Journal:  Pediatr Cardiol       Date:  2016-08-29       Impact factor: 1.655

4.  Genomewide association analysis of respiratory syncytial virus infection in mice.

Authors:  James M Stark; M Michael Barmada; Abby V Winterberg; Nilanjana Majumber; William J Gibbons; Marilyn A Stark; Maureen A Sartor; Mario Medvedovic; Jay Kolls; Kiflai Bein; Beena Mailaparambil; Marcus Krueger; Andrea Heinzmann; George D Leikauf; Daniel R Prows
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

5.  Prophylaxis of respiratory syncytial virus in Canada in 2003.

Authors:  Joan L Robinson; Bonita E Lee
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

6.  Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice.

Authors:  Laura E Luque; Olga A Bridges; John N Mason; Kelli L Boyd; Allen Portner; Charles J Russell
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

Authors:  Seung Gu Chang; Moon Sung Park; Jae Eun Yu
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

8.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03

10.  Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.

Authors:  Asunción Mejías; Octavio Ramilo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.